On April 2, 2016, the New England Journal of Medicine published the results of a study examining the effect of a combination of statin therapy and blood pressure lowering medication on preventing cardiovascular events.
The study, known as the Heart Outcomes Prevention Evaluation (“HOPE”)-3 trial, evaluated the effects of a combined therapy of a moderate dose of a potent statin and two antihypertensive agents on the prevention of major cardiovascular events. The trial participants included men 55 years of age or older, women 65 years of age or older who did not have cardiovascular disease but who did have at least one additional risk factor for CVD, and women age 60 or older who had at least two risk factors. People with cardiovascular disease or who were indicated for statins were excluded.
The study concluded that a combination of the 10 mg per day dose of the statin rosuvastatin and two antihypertensives (candesartan and hydrochlorothiazide) was associated with a significantly lower rate of cardiovascular events than dual placebo among persons at intermediate risk who did not have cardiovascular disease.
The article, “Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease,” can be found at http://www.nejm.org.